Advances and continued controversy in coronary revascularization of patients with diabetes mellitus

被引：3

作者：

John L. Petersen

Darren K. McGuire

Robert A. Harrington

机构：

[1] Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705

来源：

Current Diabetes Reports | 2003年 / 3卷 / 5期

关键词：

Diabetic Patient; Coronary Artery Bypass Graft; Abciximab; Tirofiban; Percutaneous Coronary Revascularization;

D O I：

10.1007/s11892-003-0075-0

中图分类号：

学科分类号：

摘要：

In summary, the appropriate mode of coronary revascularization for patients with diabetes remains controversial. Although current literature cannot uniformly support claims that diabetic patients benefit more from CABG or PCI, new advances in therapy may dramatically improve revascularization for these patients. Although trials are underway to address some of these issues, the role of coated stents and CABG in diabetic revascularization will not be resolved immediately. Whereas some trials may create more controversy regarding revascularization, hopefully others will shed insight into selecting appropriate procedures for the diabetic population with coronary atherosclerosis. Copyright © 2003 by Current Science Inc.

引用

页码：351 / 355

页数：4

共 30 条

[1]

Comparison of Coronary Bypass Surgery with Angioplasty in Patients with Multivessel Disease, N. Engl. J. Med., 335, pp. 217-225, (1996)

[2]

King S., Kosinski A., Guyton R., Et al., Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST), J. Am. Coll. Cardiol., 35, pp. 1116-1121, (2000)

[3]

Kurbaan S., Bowker T., Ilsley C., Difference in the mortality of the CABRI diabetic and non-diabetic populations and its relation to coronary artery disease and the revascularization mode, Am. J. Cardiol., 87, pp. 947-950, (2001)

[4]

Abizaid A., Costa M., Centemero M., Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the arterial revascularization therapy study, Circulation, 104, pp. 533-538, (2001)

[5]

Detre K., Guo P., Holubkov R., Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI), Circulation, 99, pp. 633-640, (1999)

[6]

Niles N., McGrath P., Malenka A., Et al., Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: Results from a large regional prospective study, J. Am. Coll. Cardiol., 37, pp. 1016-1018, (2001)

[7]

Beckman J., Creager M., Libby P., Diabetes and atherosclerosis: Epidemiology pathophysiology and management, JAMA, 287, pp. 2570-2581, (2002)

[8]

Rozenman Y., Sapoznikov D., Mosseri M., Et al., Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus, J. Am. Coll. Cardiol., 30, pp. 1420-1425, (1997)

[9]

Whitlow P., Dimas A., Bashore T., Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation, J. Am. Coll. Cardiol., 34, pp. 1750-1759, (1999)

[10]

Williams S., Cusco J., Roddy M., Et al., Impaired nitric oxide-mediated vasodilation in patients with non-insulin dependent diabetes mellitus, J. Am. Coll. Cardiol., 27, pp. 567-574, (1996)

← 1 2 3 →